นางสาวพรรณนลิน มหาวงศ์ธิกุล ประธานเจ้าหน้าที่บริหาร ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other Wednesday’s best-performing stocks. The stock market rebounded on ...

For Teva Pharmaceutical Industries TEVA-4.28%decrease; red down pointing triangle shareholders, a little improvement goes quite a long way. The beleaguered generic drugmaker’s third-quarter ...

Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $16.89 as of May 14th. TEVA’s forward P/E is 6.47 according to Yahoo Finance. Teva Pharmaceuticals, the world’s largest ...

Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.

On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. Teva Pharmaceutical's revenue for the second ...

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

Investors shouldn’t be surprised if a familiar risk to Teva Pharmaceutical Industries TEVA-1.53%decrease; red down pointing triangle soon resurfaces. Last October, Teva agreed to a global ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $18.38.

Teva is the world’s largest maker of generic drugs. Viatris offers an above-average dividend yield. Teva is counting on continued growth from its lead therapy, Austedo. While Teva's 2022 revenue ...

Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE:TEVA) revealed 8 unusual trades. Delving ...